TB-500 (thymosin beta-4): actin sequestration and tissue repair

TB-500 is the synthetic version of thymosin beta-4 (Tb4), a 43-amino-acid intrinsically disordered protein that sits at the center of cytoskeletal biology. it sequesters monomeric G-actin, keeps a ready reserve of actin available for rapid mobilization, and supports cell migration, angiogenesis, and tissue remodeling. it has been studied in phase 2 human trials for chronic wounds and dry eye, but no phase 3 program has been completed and it is not FDA-approved.

what is TB-500?

TB-500 is the synthetic, full-length 43-amino-acid sequence of thymosin beta-4, the same molecule that mammalian cells produce endogenously. the "TB" naming reflects its origin as a research product; the active ingredient is identical to native Tb4. the WHO-recommended international nonproprietary name for the molecule is timbetasin.

thymosin beta-4 was first isolated from bovine thymus in 1981 by Low, Hu, and Goldstein, who published the complete amino acid sequence and named the molecule for its tissue of origin [1]. over the next decade it became clear that Tb4 is not thymus-specific at all. it is expressed in essentially every nucleated cell in the body and reaches especially high concentrations inside blood platelets, where it is released at wound sites after degranulation. the molecule is small (about 4.9 kDa), acidic, and intrinsically disordered, meaning it has no fixed secondary or tertiary structure in solution and only folds into a defined shape when it binds a partner protein.

the central conserved motif of Tb4 is the LKKTET hexapeptide at residues 17 through 22. this short stretch anchors into the nucleotide-binding cleft of monomeric actin, and crystallographic work shows that the rest of the peptide wraps around the actin monomer to cap both ends [2]. the gene that encodes Tb4 (TMSB4X) sits on the X chromosome and escapes X-inactivation. TB-500 as sold commercially is the synthetic, full-length 43-amino-acid sequence; some marketing materials have historically described it as a "fragment" of Tb4 but reputable suppliers synthesize the complete protein.

how does it work?

thymosin beta-4 binds monomeric G-actin in a 1:1 complex and holds about 40 to 50 percent of the unpolymerized actin pool in reserve. when a cell receives a migratory signal, that reserve is released to profilin and the Arp2/3 complex for rapid filament assembly. on top of this primary mechanism, Tb4 engages the integrin-linked kinase (ILK) complex for Akt survival signaling, upregulates angiogenic pathways including HIF-1 alpha and VEGF, and suppresses NF-kB-driven inflammation.

the cleanest way to think about Tb4 is as an actin bank. the cell needs a large monomeric actin reserve so it can rapidly build the lamellipodia and filopodia that push the leading edge forward during migration, but free G-actin in the cytoplasm would spontaneously polymerize if it were not held in reserve. Tb4 is the principal protein that does that holding, with a dissociation constant of roughly 0.5 to 0.7 micromolar and a 1:1 binding stoichiometry. growth factor signaling triggers the withdrawal: actin is released from Tb4, handed to profilin, and assembled into new filaments at the leading edge [3].

on top of this primary actin-buffering role, Tb4 carries several signaling functions that appear at least partly independent of its actin binding. the most-studied is its interaction with integrin-linked kinase (ILK) and the adaptor protein PINCH-1, which activates downstream Akt survival signaling and supports cell survival under stress [4]. Tb4 also promotes angiogenesis through HIF-1 alpha stabilization, VEGF upregulation, and the PI3K/Akt/eNOS axis, and it suppresses inflammation by blocking nuclear translocation of the RelA/p65 subunit of NF-kB. the combination of pro-migratory, pro-angiogenic, and anti-inflammatory effects is what gives Tb4 its identity as a multifunctional tissue-repair peptide.

what does the evidence show?

the strongest TB-500 evidence is phase 2 human work in chronic wound healing (pressure ulcers and venous stasis ulcers) and ophthalmic dry eye disease, plus a small pilot in acute myocardial infarction. preclinical evidence in cardiac repair, corneal healing, hair growth, and tendon/ligament models is broad but does not yet have a published phase 3 efficacy trial in any indication.

the chronic wound program was run by RegeneRx Biopharmaceuticals and included phase 2 trials of topical Tb4 gel in pressure ulcers, venous stasis ulcers, and epidermolysis bullosa. these trials reported accelerated healing in responders compared with controls, but sample sizes were small and not all results have been published in peer-reviewed form [5]. the ophthalmic program, branded RGN-259, is currently the most clinically advanced. a phase 2 trial in dry eye showed improvement in signs and symptoms under a controlled adverse environment model [6], and phase 2/3 work in dry eye and neurotrophic keratopathy has continued through the ReGenTree US-Canada joint venture. as of mid-2026 the program had not produced a US approval.

the cardiac story is the most scientifically striking and the most uncertain. Bock-Marquette and colleagues in Nature in 2004 showed that Tb4 reduced infarct size and improved cardiac function after coronary ligation in mice through Akt activation [4], and Smart and colleagues in Nature in 2007 showed that Tb4 reactivated adult epicardial progenitor cells expressing Tbx18 and WT1, which migrated inward and differentiated into vascular cells to form new coronary vessels in the injured heart [7]. a 2016 ten-patient pilot in STEMI patients treated with Tb4-primed endothelial progenitor cells showed improved cardiac markers, but at that sample size no efficacy claim can be made. a 2012 follow-up paper by Zhou and colleagues failed to confirm the most optimistic interpretation of epicardial reprogramming, and the cardiac translation question remains genuinely unresolved.

outside these programs the evidence is mostly preclinical. rodent wound-healing studies consistently show accelerated reepithelialization, increased granulation tissue, and enhanced collagen organization. tendon and ligament models show benefit but translation to humans is poor for this class of model. hair-growth studies in rats and mice show stem-cell-driven follicle activation through the LKKTET motif, with no human data. neurological work in stroke, EAE, and traumatic brain injury models shows neuroprotective signals through anti-apoptotic and anti-inflammatory mechanisms, again without human trials. the musculoskeletal use case that drives most community demand has, paradoxically, the thinnest formal evidence of all.

FDA and regulatory status

TB-500 has never been FDA-approved for any indication. in late 2024 the FDA placed thymosin beta-4 on its Category 2 bulk drug substance list, restricting compounding under section 503A. in February 2026, HHS announced an expected reclassification toward Category 1, but the formal updated list has not been published. the World Anti-Doping Agency has banned TB-500 at all times since 2018.

the WHO recommended the international nonproprietary name "timbetasin" for thymosin beta-4 in 2018. that recommendation has not yet translated into any country-level marketing approval, and as of mid-2026 there is no approved Tb4 drug product anywhere in the world. the ophthalmic RGN-259 program is the most advanced regulatory effort, with phase 2/3 trials ongoing in the US and Canada through the ReGenTree joint venture. if RGN-259 reaches approval it would be the first Tb4-based drug to reach market, but the indication would be ophthalmic, not systemic.

WADA classifies TB-500 under category S2.3 (growth factors and growth factor modulators) and prohibits it at all times, in and out of competition. the Canadian Centre for Ethics in Sport handed a four-year ineligibility sanction to an athlete using BPC-157 and TB-500 in 2024, and validated LC-MS/MS detection methods for TB-500 in urine and plasma have been published [8]. outside formal pharmaceutical and athletic contexts, TB-500 is sold widely as a research chemical labeled "for research purposes only, not for human consumption." that labeling has no regulatory force regarding quality, and independent third-party HPLC verification of vendor product is rarely available.

safety profile and side effects

the most-reported adverse events are mild: injection-site reactions, transient fatigue or lethargy, occasional headache, and rare nausea. the most important unresolved safety question is the cancer interaction, because Tb4 is upregulated in many solid tumors and correlates with invasiveness and metastasis. long-term safety data in healthy adults using TB-500 by injection do not exist.

in the published phase 2 wound healing and dry eye trials, no serious adverse events were attributed to Tb4. injection-site irritation and mild fatigue dominate community reports. these tolerability data come from short-term studies and small samples and do not characterize chronic exposure.

the cancer interaction is the most important safety consideration and requires nuance. Tb4 expression is elevated in breast, colon, lung, pancreatic, hepatocellular, thyroid medullary, urothelial, and osteosarcoma cancers, where it correlates with increased metastatic potential, invasiveness, and angiogenesis. in pancreatic cancer cells, Tb4 overexpression stimulates proinflammatory cytokine secretion and JNK activation. the counter-evidence is real too: in multiple myeloma, Tb4 expression is lower in malignant cells than in normal plasma cells, and exogenous Tb4 has suppressed IPF-associated lung cancer in mice possibly through JAK2/STAT3 inhibition. the current interpretation is that Tb4 is more likely a marker of aggressive tumors than a direct oncogenic driver, but its pro-angiogenic and pro-migratory properties could theoretically support existing tumor growth. individuals with active or recent cancer are typically advised to avoid Tb4 and TB-500 until the relationship is better understood.

contraindications also include pregnancy and breastfeeding (no safety data), autoimmune conditions (Tb4's immune-modulating effects are not fully characterized), and pediatric use. there are no formal drug interaction studies, and the long-term consequences of repeated subcutaneous injection in healthy adults have never been formally characterized. that gap is the dominant honest framing for any chronic use discussion.

where it fits in peptide therapy

TB-500 sits in the tissue-repair peptide family alongside BPC-157 and is frequently stacked with it. its systemic, cell-migration-driven mechanism complements BPC-157's more local, NO/VEGF-driven repair signaling. it is distinct from the GH-axis peptides covered elsewhere on this site, which work through entirely different biology.

the natural comparison is with BPC-157, a 15-amino-acid pentadecapeptide derived from a gastric juice protein. BPC-157 is smaller, acts more locally at injury sites, and works primarily through nitric oxide system modulation and VEGF upregulation. TB-500 is the larger 43-amino-acid endogenous protein and acts systemically through actin sequestration, ILK/Akt survival signaling, and broader angiogenic and anti-inflammatory effects. community users often combine the two in what is sometimes called the "wolverine stack," but no controlled human trial has evaluated that combination and the synergy claim is mechanistic speculation, not demonstrated benefit.

TB-500 is mechanistically distinct from the GH-axis peptides on the rest of the site. tesamorelin, sermorelin, and the broader GHRH family work through pulsatile GH release and downstream IGF-1; ipamorelin works through the ghrelin receptor. none of these molecules share Tb4's actin-binding identity. for a broader map of how tissue repair peptides fit alongside the metabolic and neuroendocrine families, the foundational biology is covered in our free peptides and your body module.